NEW YORK (TheStreet) -- RATINGS CHANGES
Hewlett-Packard (HPQ) - Get Report was upgraded at Goldman Sachs to neutral from sell. Management has executed far more effectively than anticipated, Goldman Sachs said. Twelve-month price target is $32.
Immunogen (IMGN) - Get Report was upgraded at UBS to neutral from sell. Bullish outlook on Kadcyla and royalty revenue providing lower-risk valuation support, UBS said. Twelve-month price target is $13.
Phoenix Companies (PNX) was upgraded to hold at TheStreet Ratings.
Sprouts (SFM) - Get Report was upgraded at Credit Suisse to outperform from neutral. Twelve-month price target is $34. Pullback provides an opportunity, Credit Suisse said. Twelve-month price target is $34.
[Read: Monthly Beer Mailbag: A Gordon Biersch Birthday, SweetWater Turns Pils Pusher]
Theravance (THRX) was downgraded at Robert Baird to hold from buy. Valuation call, following the recent split, Robert Baird said.
Editor's note: To see analysts' stock comments and changes to price targets and earnings estimates, go to "Street Notes" which is available only to Real Money subscribers. To find out how to become a subscriber, please click here.
This article was written by a staff member of TheStreet.